Riley Kandel

Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.

Tycel Phillips, MD, discusses how CAR T-cell therapies and bispecific antibodies could further affect mantle cell lymphoma management.

The FDA indications for tazemetostat in relapsed/refractory follicular lymphoma and epithelioid sarcoma are being voluntarily withdrawn.

Will the FDA approve T-DXd for HER2-positve early breast cancer with residual disease after HER2-targeted neoadjuvant therapy?

Tycel Phillips, MD, discusses key questions on optimal BTK inhibitor strategies in mantle cell lymphoma.

Pirtobrutinib has been approved for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma in China.

Ashkan Emadi, MD, PhD, discusses how subcutaneous blinatumomab may represent a treatment approach in mixed phenotype acute leukemia.

Dual CD19- and CD20-targeting CAR T-cell therapy was effective and had a unique safety profile in patients with relapsed/refractory CLL.

Obinutuzumab in combination with venetoclax yielded responses in chronic lymphocytic leukemia and small lymphocytic leukemia.

An NDA for tirabrutinib in relapsed or refractory primary central nervous system lymphoma has been accepted for review by the FDA.

Alfonso Molina, MD, MPH, discusses a phase 1 trial evaluating Orca-T with allogeneic CAR T-cell therapy in high-risk B-cell acute lymphoblastic leukemia.

Ibrutinib plus bendamustine and rituximab prolonged PFS in patients with previously untreated mantle cell lymphoma who achieved a CR.

Ibrutinib plus venetoclax yielded sustained complete response rates and a favorable safety profile in relapsed/refractory mantle cell lymphoma.

The clinical benefit and disease control rates were both 100% with lurbinectedin plus ipilimumab/nivolumab in patients with advanced soft tissue sarcoma.

Nuvisertib was well tolerated with no dose-limiting toxicities and promising efficacy in relapsed/refractory myelofibrosis.

Sara Tolaney, MD, MPH, discusses the recent FDA approval of T-DXd and pertuzumab for HER2-positive breast cancer and its supporting data.

LY4170156 was well tolerated and generated promising efficacy data in patients with recurrent, platinum- resistant high-grade serous ovarian cancer.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data with an acalabrutinib-based regimen in high-risk mantle cell lymphoma from the WINDOW-3 trial.

Andrea Franson, MD, MS, discusses safety data on tovorafenib in relapsed or refractory pediatric low-grade glioma from the FIREFLY-1 trial.

Obe-cel was associated with lower rates of CRS and ICANS vs brexu-cel in relapsed or refractory acute lymphoblastic leukemia.

Zev A. Wainberg, MD, discusses different palliative chemotherapy regimens, their use cases, and other recent developments in pancreatic cancer.

Neoadjuvant SABR before nephrectomy improved 12-month RFS vs surgery alone in patients with RCC with IVC tumor thrombus, with manageable safety.

Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.

Phase 1 data showed that LP-184 displayed an acceptable safety profile and was well-tolerated in heavily-pretreated patients with advanced solid tumors.

FOG-001 demonstrated a manageable safety profile in addition to antitumor activity that was clinically meaningful in patients with desmoid tumors.

Venetoclax in combination with enzalutamide displayed a favorable safety profile as a treatment regimen for mCRPC.

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.